“Our proven GPCR structure-based drug discovery platform enabled us to rapidly advance ACCG-2671 as the lead amylin receptor agonist. We are now developing a series of amylin-based drug ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback